IP Library Granted Patent US 10,888,602
Granted Patent B2
US 10,888,602 · App. 16/534,428 · Granted Jan 12, 2021

Compositions and methods for inhibiting the biological activity of soluble biomolecules

Inventor: Louis Hawthorne (Mill Valley, CA)
Assignee: NaNotics, LLC
A61K38/191A61K38/195A61K38/2013A61K47/10A61K47/60A61K47/61A61K47/62A61K47/642A61K47/6923A61K47/6929A61K47/6937B82Y5/00B82Y30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,888,602
App. No.
16/534,428
Granted
Jan 12, 2021
Kind
B2
Abstract

The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Claims (24)

1. A particle having at least one surface, an agent immobilized on the surface, and a coating immobilized on the surface, wherein:

the agent immobilized on the surface selectively binds to a target that is a first member of a specific binding pair;

binding of the target to the agent immobilized on the surface inhibits the interaction of the target with a second member of the specific binding pair;

the target is a soluble biomolecule, and

the coating inhibits interactions between the agent immobilized on the surface and molecules on a cell surface.

2. The particle of claim 1 , wherein the target is a form of a cell surface protein.

3. The particle of claim 1 , wherein the target is a ligand for a cell surface receptor.

4. The particle of claim 1 , wherein the target is a ligand for a cytosolic receptor or a nuclear receptor.

5. The particle of claim 1 , wherein the target is a cytokine, chemokine or enzyme.

6. The particle of claim 5 , wherein the cytokine, chemokine or enzyme is expressed by a cancer cell.

7. The particle of claim 1 , wherein the target is a small molecule, an antibody, a toxin or a viral protein.

8. The particle of claim 1 , wherein the agent is a small molecule, a macrocycle compound, a polypeptide, a protein, a peptide, a peptidomimetic compound, a nucleic acid, or a nucleic acid analog.

9. The particle of claim 8 , wherein the agent is a ligand of a cell surface receptor protein.

10. The particle of claim 9 , wherein the agent is a natural ligand of a cell surface receptor protein.

11. The particle of claim 8 , wherein the agent is an antibody or a biomolecule-binding fragment of an antibody.

12. The particle of claim 11 , wherein the antibody or a biomolecule-binding fragment of an antibody is an antibody or a biomolecule-binding fragment of an antibody to a soluble tumor necrosis factor receptor protein, a toxin, or a viral protein.

13. The particle of claim 12 , wherein the antibody or a biomolecule-binding fragment of an antibody is an antibody or a biomolecule-binding fragment of an antibody to a soluble tumor necrosis factor receptor protein.

14. The particle of claim 1 , wherein the coating comprises a plurality of coating moieties or coating molecules on a surface of the particle, and the plurality of coating molecules inhibits interactions between the agent and molecules on a cell surface.

15. The particle of claim 14 , wherein the plurality of coating moieties or coating molecules is bound to a surface of the particle.

16. The particle of claim 14 , wherein the agent is a small molecule, a macrocycle compound, a polypeptide, a protein, a peptide, a peptidomimetic compound, a nucleic acid, or a nucleic acid analog.

17. The particle of claim 16 , wherein the agent is a ligand of a cell surface receptor protein.

18. The particle of claim 16 , wherein the agent is an antibody or a biomolecule-binding fragment of an antibody.

19. The particle of claim 18 , wherein the antibody or a biomolecule-binding fragment of an antibody is an antibody or a biomolecule-binding fragment of an antibody to a soluble tumor necrosis factor receptor protein, a toxin, or a viral protein.

20. The particle of claim 19 , wherein the antibody or a biomolecule-binding fragment of an antibody is an antibody or a biomolecule-binding fragment of an antibody to a soluble tumor necrosis factor receptor protein.

Assignments (3)
LIEN Recorded Jun 17, 2026
From: NANOTICS, LLC
To: FOLEY HOAG LLP
Reel/Frame 074987/0659 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2019
From: HAWTHORNE, LOUIS
To: NTERCEPT, LLC
Reel/Frame 051317/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2019
From: NTERCEPT, LLC
To: NANOTICS, LLC
Reel/Frame 051347/0777 →
Continuity (7)
Continuation 15909820 · Mar 1, 2018
Continuation 15450769 · Mar 6, 2017
Division 14873847 · Oct 2, 2015
Provisional Application 62198541 · Jul 29, 2015
Provisional Application 62198519 · Jul 29, 2015
Provisional Application 62059628 · Oct 3, 2014
Related Publication 20190358298A1 · Nov 28, 2019
Cited By (1)
US 12,685,758